Kinarus Therapeutics Holding AG / Key word(s): Miscellaneous Kinarus announces the issuance of convertible notes of up to CHF 20 million to an entity managed by Yorkville 22-Aug-2022 / 07:00 CET/CEST Release
Kinarus Therapeutics Holding AG / Key word(s): Miscellaneous Kinarus announces the issuance of convertible notes of up to CHF 20 million to an entity managed by Yorkville 22-Aug-2022 / 07:00 CET/CEST Release
Financing to be drawn in tranchesFinancing will enable Kinarus to advance the clinical development of KIN001 Basel, Switzerland, August 22, 2022. Kinarus Therapeutics Holding AG (SIX: KNRS) ("Kinarus")
Kinarus Therapeutics Holding AG / Key word(s): Conference/Research Update Kinarus Therapeutics to host KOL event on Monday, June 27, to discuss therapies in wet Age-Related Macular Degeneration and
Kinarus Therapeutics Holding AG (SIX: KNRS) ("Kinarus"), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of viral, respiratory